Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been given an average rating of “Buy” by the six ratings firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of analysts have commented on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 price objective on shares of vTv Therapeutics in a report on Friday, November 3rd. Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. Finally, Citigroup reiterated an “add” rating on shares of vTv Therapeutics in a report on Wednesday, November 8th.

A number of hedge funds have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. grew its stake in shares of vTv Therapeutics by 62.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after buying an additional 101,850 shares during the period. Bank of New York Mellon Corp grew its stake in shares of vTv Therapeutics by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,305 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of vTv Therapeutics in the 3rd quarter valued at approximately $481,000. State Street Corp grew its stake in shares of vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 1,976 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of vTv Therapeutics by 4.8% in the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 2,900 shares during the period. Institutional investors own 10.42% of the company’s stock.

vTv Therapeutics (VTVT) traded down $0.11 during mid-day trading on Friday, reaching $3.90. 32,300 shares of the company’s stock were exchanged, compared to its average volume of 30,997. vTv Therapeutics has a 12 month low of $3.57 and a 12 month high of $8.09.

TRADEMARK VIOLATION NOTICE: “vTv Therapeutics Inc. (VTVT) Receives $16.00 Average Target Price from Analysts” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/vtv-therapeutics-inc-vtvt-receives-16-00-average-target-price-from-analysts/1748162.html.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.